Editorial
Drug-induced QT Prolongation
Abstract
What do the following drugs all have in common?—grepafloxacin (Raxar), terfenadine (Seldane), cisapride (Propulsid), and astemizole (Hismanal). Each of these were once commercially available products, approved by the US Food and Drug Administration (FDA) to treat a variety of ailments. Unfortunately, postmarketing surveillance revealed that each of these agents could cause prolongation of the QT interval which potentially could lead to the development of a life threatening arrhythmia (ie, torsade de pointes).1,2,3This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.